Chimeron Bio is an early-stage biotechnology company developing innovative, off-the-shelf therapies to transform cancer treatment.
Our mission is to unlock the full potential of in vivo CAR-T by delivering multi-gene, multi-mechanism constructs directly inside the body. We aim to create potent, durable, and precise cell therapies that are both scalable and accessible. Our non-viral approach enables a new class of multiplex in vivo CAR-T treatments designed to tackle the complexity of solid tumors. In parallel, we are advancing complementary immuno-oncology programs to further our therapeutic impact.
This disruptive approach has the potential to redefine the standard for cell and gene therapies in oncology.
Company Details
- Employees
- 11
- Address
- 601 Walnut Street,
- co****@****ron.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- chimeronbio.com
- Keywords
- in 𝗖𝗔𝗥-𝗧 𝗮𝗻𝗱 𝗖𝗔𝗥-𝗡𝗞 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺𝘀.
- HQ
- Philadelphia, Pennsylvania
Chimeron Bio Questions
Chimeron Bio's website is chimeronbio.com
Chimeron Bio's LinkedIn profile is https://www.linkedin.com/company/chimeron-bio
Chimeron Bio has
11 employees.
View email and phone details for 11
employees at Chimeron Bio.
Chimeron Bio's industry is
Biotechnology Research
Chimeron Bio's top competitors are
Summit Impact Partners,
Bioagilytix,
Integral Molecular,
Aclipse Therapeutics,
Canine Biologics,
Carisma Therapeutics,
Verismo Therapeutics,
Aro Biotherapeutics,
Colorado Health & Tech Centers,
Vivodyne.
Chimeron Bio's support email address is contact@chimeron.com
Chimeron Bio's categories are Biotechnology Research
